| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Cysteine alone (100, 200 μM, 2 h) did not cause significant DNA damage, but when used in combination with O6-benzyl-N2-acetylguanosine (BNAG), it significantly increased DNA damage in M3Dau cells[3]. Cysteine (50 μM, 4 h) caused cytotoxicity in M4Beu cells, but its effect was enhanced when used in combination with 1 GgBZ (an O6-alkylguanine-DNA alkyltransferase inhibitor)[6].
|
|---|---|
| ln Vivo |
Cymustine (35 mg/kg, intravenous injection, single dose, lasting 55 days) exhibited significant diurnal toxicity variations, with the lowest toxicity level occurring 15–19 hours after the start of light exposure (HALO) and the highest toxicity level occurring 7 hours after the start of light exposure [2]. Cymustine (15 mg/kg, intravenous or direct injection into the tumor, days 1–19) induced significant changes in cell morphology, cell cycle, and melanin content in a mouse model of melanoma [4]. Cymustine (15 mg/kg, direct injection into the tumor, days 11–18) induced a novel phospholipid metabolism phenotype in melanoma tumors in a mouse model [5].
|
| Cell Assay |
RT-PCR[3]
Cell Types: M3Dau cells Tested Concentrations: 100, 200 μM or in combination with BNAG (300 μM) Incubation Duration: 2 hours or 4 hours Experimental Results: When used alone, the amplification level of DNA fragments did not change significantly. When used in combination with BNAG, it caused 1.85-fold or 2.55-fold damage, respectively. |
| Animal Protocol |
Animal/Disease Models:Active phase of circadian rhythm in male B6DZFI mice (9-10 weeks old) [2]
Doses: 35 mg/kg< Route of Administration: Intravenous injection (iv), single dose, lasting 55 days Experimental Results: Survival rates ranged from 3.8% at HALO to 87.5% and 88.2% at HALO 15 and 19, respectively. Weight loss ranged from -16.6% at HALO 15 to -27.3% at HALO 3. Animal/Disease Models:A melanoma model was established in male C57BL6/6J mice for 6-8 weeks [4]. Doses: 15 mg/kg. Route of Administration: Intravenous injection (iv) or direct injection into the tumor (it), administered on days 1, 5, and 9 after B16 cell inoculation, or on days 11, 14, and 19 after inoculation. Experimental Results: Cell morphology changed, and melanin content increased. The number of cell divisions per microscopic field decreased significantly by 10-fold. Animal/Disease Models:A melanoma model was established in male C57BL6/6J mice for 6–8 weeks [5]. Doses: 15 mg/kg Route of Administration: Directly injected into the tumor on days 11, 14, and 18 after B16 cell inoculation (it). Experimental Results: Induced a sustained redifferentiation pattern. During growth inhibition, Cho, GPC, and GPE were transiently elevated, while PC and PE were persistently elevated. During growth recovery, PC and PE were persistently overexpressed. |
| References |
| Molecular Formula |
C6H12CLN3O4S
|
|---|---|
| Molecular Weight |
257.70
|
| CAS # |
79955-36-5
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
CS(CCNC(N(N=O)CCCl)=O)(=O)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8805 mL | 19.4024 mL | 38.8048 mL | |
| 5 mM | 0.7761 mL | 3.8805 mL | 7.7610 mL | |
| 10 mM | 0.3880 mL | 1.9402 mL | 3.8805 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
